Markets

Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 20.4% - Tale of the Tape

Amicus Therapeutics, Inc. ( FOLD ) was a big mover last session, as its shares rose over 20% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company, as the stock is now up over 36% in the past one-month timeframe.

In the last 30 days, the company witnessed three positive estimate revisions and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.

Amicus Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other well-performing stocks in the biomedical/gene industry include Gilead Sciences Inc. ( GILD ), Cambrex Corporation. ( CBM ) and China Biologic Products, Inc. ( CBPO ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report

CHINA BIOLOGIC (CBPO): Get Free Report

AMICUS THERAPT (FOLD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD FOLD CBPO

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More